Proteasome inhibitor associated thrombotic microangiopathy

American Journal of Hematology

Volumn 91, Issue 9, 2016, Pages E348-E352

  Yui, Jennifer C ^a   Van Keer, Jan ^b   Weiss, Brendan M ^c   Waxman, Adam J ^c   Palmer, Matthew B ^d   D'Agati, Vivette D ^e   Kastritis, Efstathios ^f   Dimopoulos, Meletios A ^f   Vij, Ravi ^g   Bansal, Dhruv ^g   Dingli, David ^a   Nasr, Samih H ^a   Leung, Nelson ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Department of Medicine   (United States)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARFILZOMIB; COMPLEMENT COMPONENT C4; CREATININE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ECULIZUMAB; HAPTOGLOBIN; HEMOGLOBIN; IMMUNOGLOBULIN KAPPA CHAIN; INFUSION FLUID; LACTATE DEHYDROGENASE; MELPHALAN; THALIDOMIDE; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; BACTEREMIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FINGER ULCER; GASTROINTESTINAL DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HEMOLYSIS; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEUROLOGIC DISEASE; PLASMAPHERESIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TIME TO TREATMENT; TREATMENT RESPONSE; VERY ELDERLY;

EID: 84983060381     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24447     Document Type: Article

References (27)

1. George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med 2014;371:654–666.
2. Reese JA, Bougie DW, Curtis BR, et al. Drug-induced thrombotic microangiopathy: Experience of the Oklahoma registry and the bloodcenter of Wisconsin. Am J Hematol 2015;90:406–410.
3. Kojouri K, Vesely SK, George JN. Quinine-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: Frequency, clinical features, and long-term outcomes. Ann Intern Med 2001;135:1047–1051.
4. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000;342:1773–1777.
5. Pham PT, Peng A, Wilkinson AH, et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000;36:844–850.
6. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004;100:2664–2670.
7. Chan KL, Filshie R, Nandurkar H, et al. Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma. Leuk Lymph 2015;56:2185–2186.
8. Mehta N, Saxena A, Niesvizky R. Bortezomib-induced thrombotic thrombocytopaenic purpura. BMJ case Rep 2012;10:1136.
9. Salmenniemi U, Remes K. Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma. Hematol Rep 2012;4:e13.
10. Moore H, Romeril K. Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib. Inter Med J 2011;41:348–350.
11. Morita R, Hashino S, Shirai S, et al. Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma. Int J Hematol 2008;88:248–250.
12. Lodhi A, Kumar A, Saqlain MU, et al. Thrombotic microangiopathy associated with proteasome inhibitors. Clin Kidney J 2015;8:632–636.
13. Sullivan MR, Danilov AV, Lansigan F, et al. Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange. J Clin Apher 2015;30:308–310.
14. Qaqish I, Schlam IM, Chakkera HA, et al. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Transfus Apher Sci 2016;54:401–404.
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.
16. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011;364:1046–1060.
17. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487–2498.
18. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609–2617.
19. Vij R, Siegel DS, Jagannath S, et al. An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol 2012;158:739–748.
20. Siegel DS, Martin T, Wang M, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 2012;120:2817–2825.
21. Siegel D, Martin T, Nooka A, et al. Integrated safety profile of single-agent carfilzomib: Experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica 2013;98:1753–1761.
22. Field-Smith A, Morgan GJ, Davies FE. Bortezomib (Velcadetrade mark) in the treatment of multiple myeloma. Ther Clin Risk Manag 2006;2:271–279.
23. Al-Nouri ZL, Reese JA, Terrell DR, et al. Drug-induced thrombotic microangiopathy: A systematic review of published reports. Blood 2015;125:616–618.
24. George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: A systematic review of published case reports. Ann Inter Med 1998;129:886–890.
25. Izzedine H. Anti-VEGF cancer therapy in nephrology practice. Int J Nephrol 2014;2014:143426.
26. Xiao X, Zhong HY, Zhang GS, et al. Thrombotic thrombocytopenic purpura as initial and major presentation of multiple myeloma. J Thromb Thrombolysis 2013;36:422–423.
27. Yao H, Monge M, Renou M, et al. Thrombotic thrombocytopenic purpura due to anti-ADAMTS13 antibodies in multiple myeloma. Clin Nephrol 2014;81:210–215.